RxDoctor Payments Data

Vicki Fitzgerald

Family · Tupelo, MSNPI 1154563005

Payments from drug & device makers

$7,150in general payments, 2019–2025

Across 435 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Sanofi$601
  • Takeda Pharmaceuticals U.S.A., Inc.$551
  • Madrigal Pharmaceuticals$343
  • Intercept Pharmaceuticals, Inc.$308
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$7,10899%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,150 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$79,973
Medicare patients
711
Services billed
910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide117$113,892
XifaxanRifaximin15$43,315
IbsrelaTenapanor Hcl12$25,968
MovantikNaloxegol Oxalate16$7,206
Dexlansoprazole DrDexlansoprazole17$6,112
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates80$4,881
Omeprazole256$3,679
DexilantDexlansoprazole12$3,619
Pantoprazole Sodium252$3,290
Dicyclomine Hcl120$2,892
Esomeprazole Magnesium39$2,561
Famotidine149$2,333
Colestipol Hcl27$2,227
Lubiprostone26$1,850
Sucralfate48$1,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,633$113,892117 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,120$43,31515 claims
Ardelyx, Inc.Ibsrela$270$25,96812 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$551$3,61912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →